Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 57Neoplasm Metastasis 3Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Patient Preference 1Neoplasms 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Low Risk Prostate Cancer 1High-Risk and Oligometastatic Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Diseases, Male 1Castration Levels of Testosterone 1Carcinoma, Small Cell 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Prostate Carcinoma 1

Interventions

enzalutamide 1delta 24-sterol reductase 1apalutamide 1Tape Recording 1Risk Assessment 1Preoperative Exercise 1Pilot Projects 1Nutritional Support 1Focus Groups 1Exercise 1Ethanol 1Bandages, Hydrocolloid 1Adiposity 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Patient Preference × apalutamide × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡